Applying PAX-REVE 3D in your practice

Publication
Article
Dental Products ReportDental Products Report-2011-05-01
Issue 5

The PaX-Reve3D is a 3-in-1 Cone Beam CT, cephalometric and panoramic x-ray unit. With an advanced Free Field of View (FOV) function, users experience improved accuracy and efficiency of diagnosis. Furthermore, PaX-Reve3D considers the convenience of users by defining the typical default values from small to large.

The PaX-Reve3D is a 3-in-1 Cone Beam CT, cephalometric and panoramic x-ray unit. With an advanced Free Field of View (FOV) function, users experience improved accuracy and efficiency of diagnosis.

Furthermore, PaX-Reve3D considers the convenience of users by defining the typical default values from small to large.

Breakthrough FOV: This is the first dental CT that realizes the FOV function offering a customizable FOV from 5x5 to 15x15 extending the areas of diagnosis. Specific regions within the FOV are selectable based on the need or purpose of diagnosis.  

Versatility: The various FOV options deliver optimal anatomical information for better implant placement and better diagnosis of ortho, TMJ and sinus cases.

Patient Safety: With Vatech America’s philosophy to provide the optimized image quality using reduced x-ray dose, this unit features an extremely low x-ray dose. The pulsed type generator reduces radiation by 40 to 60%.

Added Plus: The One Shot Cephalometric System features an exposure time of 0.9 seconds with no image distortion and no motion artifact. 

Related Videos
2024 Chicago Dental Society Midwinter Meeting – Interview with Peter Maroon, business development and sales lead at Spectrum Solutions® on the new salivary diagnostic test, SimplyPERIO.
CDS 2024: Ivoclar's e.max ZirCAD Prime Blocks with Shashi Singhal, BDS, MS
CDS 2024: Diving Deep on J. Morita's New Root ZX3 & HF Module
CDS 2024: What's New at TAG University? with Andrew De la Rosa, DMD
CDS 2024: Breaking Down Barriers to Care with Eric Kukucka, DD
Product Bites – March 8, 2024 Part 2
Product Bites – March 8, 2024 Part 1
© 2024 MJH Life Sciences

All rights reserved.